SMSPHARMANSESMS Pharmaceuticals Limited· PharmaceuticalsHighPositive
Announced Wed, 25 Jun · 16:10 IST

SMS Pharmaceuticals Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF

SMSPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

SMS Pharmaceuticals has successfully completed its second USFDA inspection at its Central Laboratory Analytical Services facility in Gagillapur, Hyderabad. The inspection ran from June 23 to June 25, 2025, and concluded with zero Form 483 observations, meaning the US drug regulator found no adverse issues during the audit. This was the second consecutive clean inspection for this independent testing lab. The company highlighted its commitment to CGMP and GLP compliance standards across all its manufacturing and analytical facilities.

Likely market impact

Positive signal for shareholders — a clean USFDA inspection strengthens the company's credibility with global regulators and supports its ability to serve US export markets. This can boost investor confidence but typically does not cause an immediate sharp move in the stock price.